<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0"><channel><title>medsurfnews.com</title><link>http://mn.medsurfnews.com</link><description>Last resources from Medsurfnews.com</description><language>it</language><pubDate></pubDate><copyright>Healthwaregroup.com</copyright><webmaster>francesco.raimondo@healthware.it</webmaster><image><title>Medsurfnews Rss</title><url>http://mn.medsurfnews.com/images/logo.jpg</url><link>http://mn.medsurfnews.com</link></image>

	
	
<item>

<title>Route of estrogen administration and risk of venous thromboembolism</title>
<link>http://mn.medsurfnews.com/contents/en/7307/display/route-of-estrogen-administration-and-risk-of-venous-thromboembolism.aspx</link>
<pubDate>Mon, 28 May 2012 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[It is known that oral estrogen intake during menopause increases the risk of incident venous thromboembolism (VTE), and data from a few studies suggest that administration of transdermal hormone reduces this risk. To assess this difference in the clinical setting, a retrospective study was carried [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/7307_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/7307_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Estrogen vaginal ring or oxybutynin in bladder hyperactivity </title>
<link>http://mn.medsurfnews.com/contents/en/7214/display/estrogen-vaginal-ring-or-oxybutynin-in-bladder-hyperactivity-.aspx</link>
<pubDate>Mon, 23 Apr 2012 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[In postmenopausal women the presence of an overactive bladder (defined as urinary urgency and frequency with or without urge incontinence) has a 40% prevalence. To address this issue, different therapies are proposed: behavior  modification, pelvic floor physiotherapy exercises, electrostimulation, [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/7214_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/7214_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Influence of OA treatment on menstrual problems and contraception</title>
<link>http://mn.medsurfnews.com/contents/en/7151/display/influence-of-oa-treatment-on-menstrual-problems-and-contraception.aspx</link>
<pubDate>Mon, 19 Mar 2012 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[There are very few data concerning the influence of oral anticoagulant treatment (OAT) on menstruation, and not much is known on the teratogenic effect of anticoagulation drugs (warfarin is detrimental to the fetus) and thus on the need for methods of contraception during the treatment with these [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/7151_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/7151_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Proton-pump inhibitors in pregnancy</title>
<link>http://mn.medsurfnews.com/contents/en/7052/display/proton-pump-inhibitors-in-pregnancy.aspx</link>
<pubDate>Mon, 6 Feb 2012 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[Statistics show that around 3% of pregnant women make use of  proton-pump inhibitors (PPIs) before or during pregnancy. Although a few small studies confirm the safety of these drugs in pregnancy (in particular, a meta-analysis published by the American Journal of Gastroenterology in 2009 excluded [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/7052_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/7052_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Menopausal hot flashes</title>
<link>http://mn.medsurfnews.com/contents/en/6934/display/menopausal-hot-flashes.aspx</link>
<pubDate>Mon, 5 Dec 2011 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[A question women often ask is how long will their menopausal hot flashes last. The answer is that the duration generally varies between 6 months and over 5 years, with cases of women reporting hot flashes even 10 years after the final menstrual cycle. To better understand the natural course of this [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6934_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6934_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Stillbirth Risk</title>
<link>http://mn.medsurfnews.com/contents/en/6888/display/stillbirth-risk.aspx</link>
<pubDate>Mon, 21 Nov 2011 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[The rate of dead-born fetuses in industrialized countries is about 1:200 pregnancies reaching at least 22 weeks. In order to examine the risk factors for this disease, a meta-analysis has been performed on studies where researchers had considered at least one risk factor in those pregnancies ended [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6888_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6888_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>New Oral Contraceptives and Hypermenorrhea</title>
<link>http://mn.medsurfnews.com/contents/en/6803/display/new-oral-contraceptives-and-hypermenorrhea.aspx</link>
<pubDate>Mon, 24 Oct 2011 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[Normally, to control too abundant menstruations, oral contraceptives are prescribed, even if the evidence on efficacy is poor. With a randomized and double-blinded study sponsored by pharmaceutical industry, the efficacy of a new contraceptive pill, based on estradiol valerate and dienogest, has [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6803_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6803_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title> Substitutive Hormone Therapy: the Last Data from WHI</title>
<link>http://mn.medsurfnews.com/contents/en/6747/display/-substitutive-hormone-therapy-the-last-data-from-whi.aspx</link>
<pubDate>Mon, 26 Sep 2011 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[In the WHI (Women's Health Initiative) Study, 11,000 postmenopausal women undergoing hysterectomy have been treated with conjugated equine estrogens or with placebo for averagely 5.9 years; the study has been interrupted after averagely 7.1 years when it was seen that the group treated with [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6747_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6747_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>SSRIs for Menopausal Hot Flushes</title>
<link>http://mn.medsurfnews.com/contents/en/6658/display/ssris-for-menopausal-hot-flushes.aspx</link>
<pubDate>Mon, 22 Aug 2011 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[After the WHI study, researchers are more and more searching non-hormonal methods capable to control menopausal symptoms, even if the obtained results are poor and the substitutive hormone therapy remains, for the present, the only effective approach. In this study, 205 women in perimenopause and [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6658_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6658_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Polycystic Ovary Syndrome and Depression</title>
<link>http://mn.medsurfnews.com/contents/en/6645/display/polycystic-ovary-syndrome-and-depression.aspx</link>
<pubDate>Mon, 1 Aug 2011 12:00:00 +0200</pubDate>
<category>Obstetrics and Gynecology</category>
<description><![CDATA[Previous studies have marked the relationship existing between the polycystic ovary syndrome (PCOS) and the increased risk for depressive disorders; according to these marks, one has wondered whether a screening for depression is available for all the patients affected by PCOS. A meta-analysis has [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6645_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6645_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	</channel></rss>
	



